

HYPERFINE

Hyperfine Forms Global Neurosurgery Advisory Council to Support Expansion of Portable MRI in Neurosurgical Care

June 22, 2026

Leading neurosurgeons from around the world will help guide the role of the Swoop® system in neurosurgical care, including surgical workflow, product capabilities, and clinical evidence.

GUILFORD, Conn.--(BUSINESS WIRE)--Jun. 22, 2026-- [Hyperfine, Inc.](#) (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the formation of its Neurosurgery Advisory Council, a multidisciplinary group of leading neurosurgeons who will provide expertise to help inform the potential role of portable ultra-low-field MRI in neurosurgical applications and shape the future of imaging in neurosurgical care.

“The neurosurgical setting is becoming an important site of care for accessible imaging, where traditional MRI has intrinsic limitations. The Swoop® system may open up new possibilities for integrating imaging directly into surgical workflows,” said Hyperfine Chief Operating Officer Tom Teisseyre. “Providing access to imaging at key moments around a procedure may help clinical teams make better informed decisions, improve efficiency, and ultimately advance how surgical care is delivered.”

The Neurosurgery Advisory Council brings together distinguished neurosurgeons from leading academic medical centers and community hospitals around the world, representing expertise in craniotomy, endovascular neurosurgery, transsphenoidal surgery, tumor resection, and other complex procedures. Together, members will help evaluate the potential role of the Swoop® system across the neurosurgical continuum—from preoperative planning and intraoperative decision-making to postoperative monitoring and discharge. The council will provide strategic clinical guidance on workflow integration, product development, and evidence generation while sharing real-world experience that may help define best practices and expand the clinical utility of portable MRI across neurosurgical subspecialties.

“The neurosurgical community has long recognized the value of intraoperative MRI, but access has been limited by the substantial infrastructure requirements, cost, and workflow demands of having a high-field MRI system in the OR,” said Edmond Knopp, MD, Chief Medical Officer of Hyperfine. “Portable, ultra-low field MRI has the potential to fundamentally change how and where imaging is used throughout the neurosurgical care pathway. Through collaboration with leading experts in the field, we aim to accelerate its integration into clinical practice and maximize its impact on surgical decision-making and patient care.”

The initial members include:

Hakan Emmez, MD, PhD

Professor of Neurosurgery
Güven Hospital
(Ankara, Turkey)

Brian Jankowitz, MD

Chief of Neurosurgery
JFK University Medical Center
(Edison, New Jersey, USA)

Elad I. Levy, MD, MBA, FCNS

Professor and Chair
University at Buffalo Neurosurgery
(Buffalo, New York, USA)

G. Michael Lemole, Jr, MD, MBA, FAANS, FACS

Neurosurgeon (Skull Base and Cranial Surgery) at Jefferson Abington Hospital
Professor, Department of Neurological Surgery at Thomas Jefferson University
(Abington, Pennsylvania, USA)

Debraj "Raj" Mukherjee, MD, MPH

Associate Professor and Assistant Residency Program Director
Department of Neurosurgery
Johns Hopkins Medical Institutions
(Baltimore, Maryland, USA)

Todd Patrick, MD, PhD

Chief of Neurosurgery
Christus Trinity Mother Frances Health System
(Tyler, Texas, USA)

Michael Schulder, MD, FAANS

Professor and Vice Chairman, Department of Neurosurgery
Zucker School of Medicine at Hofstra/Northwell
(Manhasset, New York, USA)

Adnan Siddiqui, MD, PhD, FAHA

Vice-Chairman and Professor of Neurosurgery
Jacobs School of Medicine & Biomedical Sciences
(Buffalo, New York, USA)

Julian Spears, MD, SM, FRCS(C), FACS

Head, Division of Neurosurgery
Chair in Brain Tumor and Cerebrovascular Surgery
St. Michael's Hospital, Unity Health Toronto
Department of Surgery, University of Toronto
(Toronto, Ontario, Canada)

By convening leading neurosurgeons across subspecialties and care settings, Hyperfine aims to accelerate evaluation of portable MRI in neurosurgical workflows and help expand the clinical utility of the Swoop® system in this important area of care.

For more information about the Swoop® system, please visit [HyperfineMRI.com](https://www.hyperfineMRI.com).

About the Swoop® Portable MRI Systems

The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

About Hyperfine, Inc.

Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit [HyperfineMRI.com](https://www.hyperfineMRI.com).

Hyperfine, the Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s goals and commercial plans, the benefits of the Company’s products and services, and the Company’s future performance and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the Company’s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future ; the inability of the Company to progress on product advancements and improvements ; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services and reimbursement for medical procedures conducted using the Company’s products and services; existing and potential future National Institutes of Health funding pressures; existing and potential future effects from U.S. export controls and tariffs; the Company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties indicated from time to time in the Company’s filings with the Securities and Exchange Commission, including those under “Risk Factors” therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260622808552/en/>

Media Contact

Devin Zell
Hyperfine
dzell@hyperfine.io

Investor Contact

Webb Campbell
Gilmartin Group LLC

webb@gilmartinir.com

Source: Hyperfine, Inc.